# FIGHT-202: pemigatinib for previously treated cholangiocarcinoma with FGFR2 fusions or rearrangements

Source: https://onco.cc/key-papers/paper-fight-202-pemigatinib-lancet-oncol-2020/  
OnCo record `paper-fight-202-pemigatinib-lancet-oncol-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The FGFR inhibitor pemigatinib shrank tumours in more than a third of patients with previously treated intrahepatic cholangiocarcinoma carrying FGFR2 fusions, the first targeted drug approved for the disease.

## Summary

Phase 2 study of 146 patients with previously treated locally advanced or metastatic cholangiocarcinoma, including 107 with FGFR2 fusions or rearrangements, treated with pemigatinib 13.5 mg daily on a two-weeks-on, one-week-off schedule.

In FGFR2-rearranged patients objective response was 35.5 percent with median duration of response 7.5 months and median progression-free survival 6.9 months; no responses were seen in patients with other FGF/FGFR alterations. Hyperphosphataemia was almost universal.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: The Lancet Oncology
- Year: 2020
- DOI: 10.1016/S1470-2045(20)30109-1
- Authors: Abou-Alfa GK, Sahai V, Hollebecque A, et al.
- Findings: Objective response 35.5 percent in FGFR2-rearranged cholangiocarcinoma.; Median progression-free survival 6.9 months; median overall survival 21.1 months.
- What it means: FGFR2 fusion testing is standard in intrahepatic cholangiocarcinoma, and pemigatinib (with futibatinib) is the second-line targeted option for fusion-positive disease.
- Caveats: Single-arm; the confirmatory first-line trial (FIGHT-302) is ongoing.; Hyperphosphataemia, eye toxicity and nail changes require monitoring.

## Sources

- Lancet Oncol 2020: https://doi.org/10.1016/S1470-2045(20)30109-1
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32203698/

## Connected records

- cancers: [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- drugs: [Pemigatinib](https://onco.cc/drugs/pemigatinib/)
- trials: [FIGHT-202](https://onco.cc/trials/fight-202/)
- journals: [The Lancet Oncology](https://onco.cc/journals/lancet-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-fight-202-pemigatinib-lancet-oncol-2020.json